IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Goldline Pharmaceutical IPO is a Book Building listing on BSE SME exchange, with an ipo size of ₹ [●] Cr. The company is based in Nagpur and caters to Pharmaceutical sector. Cumulative Capital is the merchant banker of Goldline Pharmaceutical IPO. It is a SME Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 30th September 2025.
Goldline Pharmaceutical IPO posted revenues of ₹ 28.06 Cr. and PAT of ₹ 2.83 Cr. in FY25 on annualised basis.
Revenue:
₹ 28.06 Cr.
EBITDA Margin:
20.78
% 
Net Worth: ₹ 10.35 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: 1.68 times
Financial results of Goldline Pharmaceutical IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
| Financials | FY25 | FY24 | FY23 | ||
|---|---|---|---|---|---|
|
Balance Sheet
|
|||||
| Assets | 26.28 | 22.93 | 19.38 | ||
| Net Worth | 10.35 | 7.87 | 5.89 | ||
| Total Debt | 11.03 | 11.13 | 10.82 | ||
|
Profit & Loss
|
|||||
Revenue
Revenue on annualised basis |
28.06 | 23.57 | 19.85 | ||
EBITDA
EBITDA on annualised basis |
5.83 | 4.30 | 2.19 | ||
PAT
PAT on annualised basis |
2.83 | 1.81 | 0.26 | ||
Goldline Pharmaceutical IPO PAT Margin is 10.09 % , ROCE (Return on Capital Employed) is 38.46 % as per latest financial. The below table shows Goldline Pharmaceutical IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
| Particulars | FY25 | FY24 | FY23 |
|---|---|---|---|
| EBITDA Margin (%) | 20.78 | 18.24 | 11.03 |
| PAT Margin (%) | 10.09 | 7.68 | 1.31 |
| EPS (₹) | 4.11 | 3.01 | 0.43 |
| ROE (%) | 27.34 | 23.00 | 4.41 |
| ROCE (%) | 38.46 | 32.41 | 19.43 |
| ROA (%) | 10.77 | 7.89 | 1.34 |
| Debt to Equity | 1.07 | 1.41 | 1.84 |
The market Capitalisation of Goldline Pharmaceutical IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Goldline Pharmaceutical IPO prospectus highlights an Return on Equity (ROE) of 27.34 % , Return on Assets (ROA) of 10.77 %, and an EBITDA Margin of 20.78 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Goldline Pharmaceutical IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Goldline Pharmaceutical IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Goldline Pharmaceutical IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Goldline Pharmaceutical IPO reported revenue of ₹ 28.06 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Goldline Pharmaceutical IPO provide insights into sales growth, market demand, and business scalability.
Goldline Pharmaceutical recorded an EBITDA of ₹ 5.83 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Goldline Pharmaceutical Profit After Tax (PAT) is ₹ 2.83 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 28.06 Cr.
EBITDA Margin:
20.78
%
Net Worth: ₹ 10.35 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA:
[●]
Goldline Pharmaceutical operates in Pharmaceutical and Engaged In The Business Of Marketing Pharmaceutical Products. The Issue is listed on BSE SME in Oct, 2025. Goldline Pharmaceutical IPO size was with Issue price of .
Merchant Banker(s) of Goldline Pharmaceutical IPO: Cumulative Capital Private Limited
Goldline Pharmaceutical IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Goldline Pharmaceutical IPO listed at a listing price of against the offer price of .
The current market price of Goldline Pharmaceutical is .
Why Us?
